113.27 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||113.20 x 800|
|Ask||113.35 x 1300|
|Day's Range||113.25 - 113.54|
|52 Week Range||34.53 - 114.20|
|Beta (3Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.41|
The groundwork for the proposed $4.8 billion sale of Philadelphia gene therapy pioneer Spark Therapeutics to Roche actually began last spring and would eventually involve three potential suitors, according to documents filed with Securities and Exchange Commission related to the proposed transaction. Founded in 2013 when it was spun out of Children's Hospital of Philadelphia, Spark earned the distinction of being the first company to received Food and Drug Administration approval for gene therapy to treat a genetic disease. May 2018 to August 2018: Spark engages in discussions Roche Holdings and two other undentified global biotechnology and pharmaceutical companies regarding a potential hemophilia A collaboration. December 2018.
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.
Pennsylvania's life sciences industry honored its own Wednesday night as awards where handed out at Life Sciences Pennsylvania's annual dinner. The event at the Pennsylvania Convention Center drew a record crowd of more than 1,300 people. The awards include two named in honor of biotech pioneer's Hubert J. P. Schoemaker, the co-founder of Centocor, and Frank Baldino Jr., the co-founder of Cephalon.
WILMINGTON, Del., March 12, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Spark Therapeutics, Inc. (NASDAQ GS: ONCE)? Did you purchase any of your shares prior to.
NEW YORK , March 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York ...
Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc. (ONCE) at a price of US$ 114.50 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 22 February 2019 among Spark Therapeutics, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 022019 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. The tender offer period will expire at 12am midnight, Eastern Time, at the end of the day on 3 April 2019, unless the offer is extended.
Now that Spark Therapeutics (NASDAQ: ONCE) agreed on a definitive merger with Roche (OTCMKTS:RHHBY) for $114.50 a share, only one question remains for investors. Should investors keep holding Spark stock now and after the deal is done? Probably, and here's why.Source: Shutterstock Spark Stock and the MergerTo assess the merits of the deal, look at the price Roche paid. Both Roche and Spark investors need to ask why the former was willing to pay a premium of over 200% to acquire the latter. The total value of the deal, at the time of the announcement on Feb. 25, is $4.8 billion.Spark's acquisition risk is high, too, because it only has one marked product. Voretigene neparvovec, or Luxturna, is a gene therapy that treats Leber's congenital amaurosis. Novartis AG (NYSE: NVS) is responsible for the marketing aspect of the therapy.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Trade War Stocks to Sell on U.S.-China Deal News Roche has plenty of strong sales growth in its two main divisions: pharmaceuticals and diagnostics. In the fourth quarter, sales grew in the high single digits. In fact, sales grew for seven consecutive years. It stands to reason that Roche wants Spark to get ahead in the gene therapy market.When it comes to treating genetic diseases, Spark has a fully integrated offering. Plus, Spark is the only biotechnology company that successfully commercialized a gene therapy in the U.S. market. With that achievement, Roche needs Spark Therapeutics to get ahead.Spark's CEO Jeffrey D. Marrazzo said that genetic diseases are immediate and vast, so it will need Roche's resources and reach to accelerate the development of more gene therapies. Spark's ProgramsSpark will have full autonomy under The Roche Group and will build on its hemophilia A program. In 2018, Luxturna launched in the U.S. with great success. The company demonstrated it could commercialize the drug and secure patient access.It cut most of the risk with the launch and after establishing treatment centers, patients have a channel for market access and reimbursement. Completing a licensing agreement with Novartis will help drive uptake for the therapy outside of the U.S.Spark has a few products whose developments within the hemophilia programs progressed. SPK-9001 for hemophilia B was transitioned to Pfizer (NYSE: PFE). SPK-8001 and SPK-8016 for hemophilia A progressed last year.The FDA designated SPK-8001 breakthrough therapy designation. And last December, the company shared the drug's safety profile at ASH; 9.7 years after follow-up, subjects showed no inhibitors, no thrombotic events, and no persistent or unresolved transaminase elevations.Spark's Phase I/II study of 8016 are underway. When the company shares the updated data in mid-2019, it may further validate Roche's purchase of the company.Spark is also targeting the inhibitor population, which would increase the addressable market of the therapy. Inhibitors, or neutralizing antibodies to factor VIII, occur in as many as 30% of the population who have severe or moderately severe hemophilia A. Earnings and Spark StockSpark reported revenue of $64.7 million last year, with $27 million from net product sales of Luxturna. $37.8 million comes from the company's agreement with Pfizer and Novartis.Despite R&D costs falling after the commercialization of Luxterna, SG&A costs still rose last year. It rose to $124.9 million, up from $111.1 million from the prior year. These costs are due primarily to higher salaries and stock-based compensation. For the year, Spark lost $78.8 million, or $2.11 a share. Investing StrategyInvestors may look at holding Roche stock for the long-term in light of the Spark acquisition. Roche is well-diversified and has a healthy cash flow to fund the costs related to this deal. Still, the pay-off will likely take at least a year, if not more.This is due to shares trading close to yearly highs, plus unforeseen write-offs related to this acquisition that may shake investor confidence. Fortunately, shares pay a dividend yielding 3.1%, so investors will still earn regular income while waiting patiently for the stock to go up.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Blue-Chip Stocks That Will Lose You Money * 7 Cheap Stocks Under $5 That Could Soar * 7 Stocks Under $10 You Shouldn't Buy Compare Brokers The post The Roche Merger Will Do Wonders for Spark Stock appeared first on InvestorPlace.
Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ONCE with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 28. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ONCE had net inflows of $1.31 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Biotech stocks took a tumble on Monday with the XBI S&P biotech ETF and IBB Nasdaq biotech ETF each falling. One of those is your best bet for a bounce.
NEW YORK, March 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
It’s only a matter of time until the first million-dollar drug arrives in a deeply dysfunctional health-care system. The age of gene therapy promises a wave of life-changing and life-saving medicines. Some have been approved, like Luxturna from Spark Therapeutics, which treats a hereditary disease that causes blindness and affects roughly 2,000 patients in the U.S. Roche agreed to buy the company this week for more than double its previous market value, in large part for some promising treatments for hemophilia.
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
What to Expect from Roche’s Acquisition of Spark Therapeutics(Continued from Prior Part)First commercialized assetOn December 19, 2017, Spark Therapeutics (ONCE) issued a press release announcing FDA approval for its gene therapy, Luxturna, to
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
What to Expect from Roche’s Acquisition of Spark Therapeutics(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Roche Holdings (RHHBY) reported total sales of 56.8 billion Swiss francs, a YoY rise of 7% on a reported basis as
What to Expect from Roche’s Acquisition of Spark TherapeuticsAcquisition announcement On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE) for a
NEW YORK, Feb. 26, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
A windfall awaits company executives, board members and Children's Hospital of Philadelphia once the Roche deal is completed.